- Document Number:
20210169835
- Appl. No:
17/086639
- Application Filed:
November 02, 2020
- نبذة مختصرة :
The present invention relates to methods, compositions, and unit dosage forms useful for selectively modulating mTORC1 activity.
- Claim:
1. A method of treating treatment resistant depression in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a pharmaceutically acceptable composition comprising compound A: [chemical expression included] or a pharmaceutically acceptable salt thereof; wherein the therapeutically effective amount comprises a total daily dose of about 100 mg to about 3000 mg; and wherein the treatment resistant depression is resistant to one or more first line treatments.
- Claim:
2. (canceled)
- Claim:
3. The method according to claim 1, wherein the therapeutically effective amount comprises a total daily dose of about 150 mg, about 300 mg, about 400 mg, about 600 mg, about 800 mg, about 1000 mg, about 1600 mg, about 2400 mg, or about 3000 mg.
- Claim:
4. The method according to claim 1, wherein the total daily dose is administered QD.
- Claim:
5. The method according to claim 1, comprising administering a single dose.
- Claim:
6. The method according to claim 1, comprising administering at least two doses.
- Claim:
7. The method according to claim 1, comprising administering compound A daily for at least two, three, four, five, six, or seven consecutive days.
- Claim:
8. The method according to claim 6, comprising administering a first dose about 48 hours prior to administering a second dose.
- Claim:
9. The method according to claim 1, wherein the total daily dose is administered under fasted conditions.
- Claim:
10. The method according to claim 1, wherein the total daily dose is administered under fed conditions.
- Claim:
11-12. (canceled)
- Claim:
13. The method according to claim 1, wherein the treatment resistant depression is resistant to second line treatments.
- Claim:
14. The method according to claim 1, wherein the patient is diagnosed with major depressive disorder (“MDD”).
- Claim:
15. The method according to claim 1, wherein the patient is experiencing a depressive episode and has had at least one inadequate response to at least one antidepressant during the depressive episode.
- Claim:
16. The method according to claim 15, wherein the patient is experiencing a depressive episode and has had at least one inadequate response to at least two, three, or four different antidepressants during the depressive episode.
- Claim:
17. The method according to claim 1, wherein the patient is assessed to have a Montgomery-Asberg Depression Rating Scale (MADRS) total score of ≥21 prior to treatment.
- Claim:
18. The method according to claim 1, wherein the patient is assessed to have a Raskin Depression Rating Scale score of ≥9 prior to treatment.
- Claim:
19. The method according to claim 1, wherein administration is oral.
- Claim:
20. The method according to claim 1, wherein the total daily dose is a single unit dosage form.
- Claim:
21. The method according to claim 2, wherein the total daily dose comprises a liquid unit dosage form comprising about 150 mg, about 300 mg, about 400 mg, about 600 mg, about 800 mg, about 1000 mg, about 1600 mg, about 2400 mg, or about 3000 mg of compound A, or pharmaceutically acceptable salt thereof.
- Claim:
22. The method according to claim 21, wherein the total daily dose comprises a liquid unit dosage form comprising about 2400 mg of compound A, or pharmaceutically acceptable salt thereof.
- Current International Class:
61; 61; 61
- الرقم المعرف:
edspap.20210169835
Processing Request
No Comments.